Ole-Petter Riksfjord Hamnvik, M.B.,Ch.B.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fanconi Syndrome | 2 | 2014 | 35 | 0.890 |
Why?
|
Leptin | 6 | 2014 | 1599 | 0.650 |
Why?
|
Hypothyroidism | 4 | 2018 | 667 | 0.570 |
Why?
|
Transsexualism | 1 | 2019 | 210 | 0.510 |
Why?
|
Hyperglycemia | 2 | 2021 | 1388 | 0.480 |
Why?
|
Reverse Transcriptase Inhibitors | 2 | 2014 | 620 | 0.450 |
Why?
|
Education, Medical, Continuing | 1 | 2019 | 829 | 0.440 |
Why?
|
Transglutaminases | 1 | 2014 | 200 | 0.430 |
Why?
|
Lectins | 2 | 2016 | 490 | 0.420 |
Why?
|
Bone Diseases, Metabolic | 2 | 2014 | 411 | 0.420 |
Why?
|
Hypokalemia | 1 | 2014 | 152 | 0.410 |
Why?
|
Receptors, Leptin | 2 | 2013 | 352 | 0.410 |
Why?
|
Cachexia | 1 | 2014 | 202 | 0.400 |
Why?
|
Adenine | 2 | 2014 | 995 | 0.370 |
Why?
|
Immunoglobulin A | 1 | 2014 | 992 | 0.360 |
Why?
|
GTP-Binding Proteins | 1 | 2014 | 948 | 0.350 |
Why?
|
Diabetes Insipidus | 1 | 2010 | 144 | 0.340 |
Why?
|
Energy Metabolism | 4 | 2016 | 2907 | 0.330 |
Why?
|
Hepatitis B, Chronic | 1 | 2014 | 413 | 0.330 |
Why?
|
Hyperthyroidism | 1 | 2011 | 292 | 0.330 |
Why?
|
Antineoplastic Agents | 3 | 2021 | 13676 | 0.320 |
Why?
|
Pituitary Diseases | 1 | 2010 | 137 | 0.320 |
Why?
|
Hypoglycemic Agents | 4 | 2013 | 3109 | 0.310 |
Why?
|
Thyroid Hormones | 1 | 2011 | 407 | 0.310 |
Why?
|
Hepatitis B | 1 | 2014 | 711 | 0.300 |
Why?
|
Intestine, Small | 1 | 2014 | 1217 | 0.300 |
Why?
|
Celiac Disease | 1 | 2014 | 820 | 0.270 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2019 | 12252 | 0.260 |
Why?
|
Thyroid Gland | 1 | 2011 | 1171 | 0.240 |
Why?
|
Antihypertensive Agents | 1 | 2014 | 2029 | 0.240 |
Why?
|
Gender Identity | 2 | 2021 | 770 | 0.230 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2188 | 0.220 |
Why?
|
Neoplasms | 6 | 2021 | 22371 | 0.220 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2014 | 3514 | 0.220 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 3837 | 0.210 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2021 | 125 | 0.180 |
Why?
|
Adiposity | 1 | 2010 | 1895 | 0.180 |
Why?
|
Phosphatidylinositols | 1 | 2021 | 280 | 0.180 |
Why?
|
Cytokines | 2 | 2016 | 7453 | 0.170 |
Why?
|
Blood Glucose | 3 | 2016 | 6430 | 0.170 |
Why?
|
Obesity | 4 | 2016 | 13090 | 0.170 |
Why?
|
Densitometry | 1 | 2019 | 151 | 0.160 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2019 | 169 | 0.150 |
Why?
|
Protein Kinase Inhibitors | 3 | 2021 | 5703 | 0.150 |
Why?
|
Hypothalamus | 2 | 2015 | 1004 | 0.150 |
Why?
|
Spirometry | 1 | 2021 | 929 | 0.140 |
Why?
|
Diabetes Complications | 2 | 2017 | 1320 | 0.140 |
Why?
|
Models, Educational | 1 | 2019 | 375 | 0.140 |
Why?
|
Sirolimus | 2 | 2021 | 1540 | 0.130 |
Why?
|
GPI-Linked Proteins | 2 | 2016 | 472 | 0.130 |
Why?
|
Problem-Based Learning | 1 | 2019 | 360 | 0.130 |
Why?
|
Graves Ophthalmopathy | 1 | 2018 | 135 | 0.130 |
Why?
|
Education, Distance | 1 | 2019 | 260 | 0.130 |
Why?
|
Thyroid Function Tests | 2 | 2018 | 289 | 0.120 |
Why?
|
Nephrosis, Lipoid | 1 | 2015 | 46 | 0.120 |
Why?
|
Bone Density | 3 | 2019 | 3573 | 0.120 |
Why?
|
Angiotensins | 1 | 2015 | 141 | 0.120 |
Why?
|
Hypertension | 1 | 2014 | 8616 | 0.110 |
Why?
|
Periodontal Diseases | 1 | 2017 | 455 | 0.110 |
Why?
|
Amenorrhea | 3 | 2012 | 484 | 0.110 |
Why?
|
Humans | 36 | 2021 | 768166 | 0.110 |
Why?
|
Hypothalamic Diseases | 2 | 2012 | 134 | 0.110 |
Why?
|
Osteomalacia | 1 | 2014 | 60 | 0.110 |
Why?
|
Orchiectomy | 1 | 2016 | 466 | 0.110 |
Why?
|
Neurosecretory Systems | 2 | 2012 | 223 | 0.110 |
Why?
|
Adiponectin | 2 | 2016 | 1117 | 0.110 |
Why?
|
gamma-Glutamyltransferase | 1 | 2014 | 144 | 0.110 |
Why?
|
Insulin Resistance | 5 | 2016 | 3986 | 0.110 |
Why?
|
Waist-Hip Ratio | 2 | 2014 | 520 | 0.110 |
Why?
|
Hypophosphatemia | 1 | 2014 | 93 | 0.110 |
Why?
|
Electrolytes | 1 | 2014 | 279 | 0.100 |
Why?
|
Osteocalcin | 1 | 2013 | 275 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2021 | 2457 | 0.100 |
Why?
|
Liver Function Tests | 1 | 2014 | 526 | 0.100 |
Why?
|
Aspartate Aminotransferases | 1 | 2014 | 414 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2021 | 2062 | 0.100 |
Why?
|
Oral Health | 1 | 2017 | 493 | 0.100 |
Why?
|
Laparotomy | 1 | 2014 | 458 | 0.100 |
Why?
|
Circadian Rhythm | 2 | 2014 | 2593 | 0.100 |
Why?
|
Thyroxine | 1 | 2015 | 665 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2021 | 2885 | 0.100 |
Why?
|
Pelvic Bones | 1 | 2014 | 274 | 0.100 |
Why?
|
Radioimmunotherapy | 1 | 2011 | 93 | 0.090 |
Why?
|
Tetrahydronaphthalenes | 1 | 2011 | 85 | 0.090 |
Why?
|
Radiography, Abdominal | 1 | 2014 | 541 | 0.090 |
Why?
|
Thyroiditis, Autoimmune | 1 | 2011 | 101 | 0.090 |
Why?
|
Alanine Transaminase | 1 | 2014 | 606 | 0.090 |
Why?
|
Fasting | 2 | 2014 | 1610 | 0.090 |
Why?
|
Nausea | 1 | 2014 | 682 | 0.090 |
Why?
|
Diphtheria Toxin | 1 | 2011 | 253 | 0.090 |
Why?
|
Diagnosis, Differential | 3 | 2015 | 13014 | 0.090 |
Why?
|
Lymphocytes | 2 | 2016 | 2614 | 0.090 |
Why?
|
Tietze's Syndrome | 1 | 2009 | 2 | 0.090 |
Why?
|
Phosphates | 1 | 2014 | 765 | 0.090 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2010 | 87 | 0.090 |
Why?
|
Renin-Angiotensin System | 1 | 2015 | 737 | 0.090 |
Why?
|
Antibodies, Neoplasm | 1 | 2011 | 283 | 0.090 |
Why?
|
Body Fat Distribution | 1 | 2011 | 246 | 0.090 |
Why?
|
Anticarcinogenic Agents | 1 | 2011 | 251 | 0.080 |
Why?
|
Learning | 1 | 2019 | 1759 | 0.080 |
Why?
|
Osteoporosis | 1 | 2019 | 1605 | 0.080 |
Why?
|
Hypopituitarism | 1 | 2011 | 253 | 0.080 |
Why?
|
Homeodomain Proteins | 2 | 2016 | 2429 | 0.080 |
Why?
|
Blood Pressure | 3 | 2014 | 8543 | 0.080 |
Why?
|
Abdominal Pain | 1 | 2014 | 1070 | 0.070 |
Why?
|
Cardiovascular Diseases | 3 | 2014 | 15662 | 0.070 |
Why?
|
Insulin | 4 | 2016 | 6607 | 0.070 |
Why?
|
Iodine Radioisotopes | 1 | 2011 | 1034 | 0.070 |
Why?
|
Craniopharyngioma | 1 | 2010 | 279 | 0.070 |
Why?
|
Acidosis, Lactic | 1 | 2009 | 145 | 0.070 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2016 | 1536 | 0.070 |
Why?
|
Chest Pain | 1 | 2014 | 1101 | 0.070 |
Why?
|
Education, Medical | 1 | 2019 | 1742 | 0.070 |
Why?
|
Interferon-alpha | 1 | 2011 | 910 | 0.070 |
Why?
|
Bariatric Surgery | 2 | 2014 | 1001 | 0.070 |
Why?
|
Homeostasis | 2 | 2016 | 3348 | 0.070 |
Why?
|
Androgen Antagonists | 1 | 2016 | 1412 | 0.070 |
Why?
|
Education, Medical, Graduate | 1 | 2019 | 2420 | 0.070 |
Why?
|
Male | 24 | 2019 | 364719 | 0.070 |
Why?
|
Reproduction | 1 | 2011 | 646 | 0.070 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2014 | 957 | 0.070 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2008 | 147 | 0.070 |
Why?
|
Thalidomide | 1 | 2011 | 886 | 0.070 |
Why?
|
Thiazolidinediones | 1 | 2009 | 461 | 0.060 |
Why?
|
Administration, Oral | 2 | 2016 | 4030 | 0.060 |
Why?
|
Pilot Projects | 1 | 2019 | 8741 | 0.060 |
Why?
|
Curriculum | 1 | 2019 | 3782 | 0.060 |
Why?
|
Sex Factors | 3 | 2014 | 10632 | 0.060 |
Why?
|
Weight Loss | 2 | 2014 | 2721 | 0.060 |
Why?
|
Adult | 10 | 2016 | 223646 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2014 | 10760 | 0.060 |
Why?
|
Cholesterol, LDL | 2 | 2014 | 2403 | 0.060 |
Why?
|
Metformin | 2 | 2010 | 909 | 0.060 |
Why?
|
Lipids | 1 | 2016 | 3343 | 0.060 |
Why?
|
Interleukin-2 | 1 | 2011 | 1895 | 0.060 |
Why?
|
Diabetes Mellitus | 3 | 2017 | 5889 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2014 | 3228 | 0.060 |
Why?
|
Cholesterol, HDL | 1 | 2010 | 1820 | 0.060 |
Why?
|
Hypogonadism | 1 | 2010 | 805 | 0.060 |
Why?
|
Cyprus | 2 | 2014 | 96 | 0.050 |
Why?
|
Recombinant Fusion Proteins | 1 | 2011 | 3740 | 0.050 |
Why?
|
Radiography | 1 | 2014 | 6983 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4352 | 0.050 |
Why?
|
Anorexia Nervosa | 1 | 2012 | 1364 | 0.050 |
Why?
|
Biopsy | 1 | 2014 | 6793 | 0.050 |
Why?
|
Risk Assessment | 3 | 2014 | 24315 | 0.050 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2011 | 2433 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2019 | 4887 | 0.050 |
Why?
|
Pituitary Neoplasms | 1 | 2010 | 1322 | 0.050 |
Why?
|
Recombinant Proteins | 1 | 2011 | 6514 | 0.050 |
Why?
|
Hypoglycemia | 1 | 2009 | 895 | 0.050 |
Why?
|
Body Mass Index | 3 | 2014 | 13053 | 0.050 |
Why?
|
Staphylococcus aureus | 1 | 2009 | 1430 | 0.050 |
Why?
|
Cholesterol | 1 | 2010 | 2914 | 0.050 |
Why?
|
Monitoring, Physiologic | 1 | 2009 | 1798 | 0.050 |
Why?
|
Female | 15 | 2019 | 397192 | 0.050 |
Why?
|
Adaptive Immunity | 2 | 2016 | 733 | 0.040 |
Why?
|
Staphylococcal Infections | 1 | 2009 | 1398 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2014 | 15454 | 0.040 |
Why?
|
Risk Factors | 5 | 2018 | 74944 | 0.040 |
Why?
|
Signal Transduction | 2 | 2014 | 23645 | 0.040 |
Why?
|
Bone Marrow Cells | 1 | 2008 | 2414 | 0.040 |
Why?
|
Molecular Targeted Therapy | 1 | 2011 | 2830 | 0.040 |
Why?
|
Kidney | 1 | 2015 | 7064 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2015 | 3187 | 0.040 |
Why?
|
Testosterone | 1 | 2010 | 2491 | 0.040 |
Why?
|
Adipose Tissue | 1 | 2011 | 3329 | 0.040 |
Why?
|
Middle Aged | 12 | 2018 | 223492 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2009 | 6316 | 0.040 |
Why?
|
Pain | 1 | 2014 | 5100 | 0.040 |
Why?
|
Knowledge | 1 | 2019 | 178 | 0.040 |
Why?
|
Ireland | 1 | 2017 | 170 | 0.040 |
Why?
|
Age Factors | 1 | 2014 | 18412 | 0.040 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2008 | 1437 | 0.040 |
Why?
|
Disease Progression | 1 | 2014 | 13671 | 0.040 |
Why?
|
Aged | 8 | 2018 | 171504 | 0.030 |
Why?
|
Peptide YY | 1 | 2016 | 135 | 0.030 |
Why?
|
Incretins | 1 | 2016 | 100 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2011 | 9263 | 0.030 |
Why?
|
Fatty Acids, Nonesterified | 1 | 2016 | 394 | 0.030 |
Why?
|
Ghrelin | 1 | 2016 | 251 | 0.030 |
Why?
|
C-Peptide | 1 | 2016 | 443 | 0.030 |
Why?
|
Glucagon | 1 | 2016 | 535 | 0.030 |
Why?
|
Seminal Plasma Proteins | 1 | 2013 | 11 | 0.030 |
Why?
|
Smoking | 1 | 2010 | 9092 | 0.030 |
Why?
|
Lipodystrophy, Congenital Generalized | 1 | 2013 | 10 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2016 | 11101 | 0.030 |
Why?
|
Hyponatremia | 1 | 2015 | 279 | 0.030 |
Why?
|
Prospective Studies | 3 | 2014 | 54926 | 0.030 |
Why?
|
Fibronectins | 1 | 2016 | 722 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2009 | 10399 | 0.020 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 1 | 2013 | 138 | 0.020 |
Why?
|
Thyrotropin | 1 | 2015 | 834 | 0.020 |
Why?
|
Edema | 1 | 2015 | 765 | 0.020 |
Why?
|
Lymphoma, Follicular | 1 | 2015 | 460 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2016 | 2230 | 0.020 |
Why?
|
Young Adult | 3 | 2016 | 60066 | 0.020 |
Why?
|
Cohort Studies | 2 | 2010 | 41754 | 0.020 |
Why?
|
United States | 1 | 2019 | 73039 | 0.020 |
Why?
|
SEER Program | 1 | 2016 | 1444 | 0.020 |
Why?
|
Lipocalins | 1 | 2011 | 161 | 0.020 |
Why?
|
Leg | 1 | 2015 | 1088 | 0.020 |
Why?
|
Acute-Phase Proteins | 1 | 2011 | 252 | 0.020 |
Why?
|
Floxacillin | 1 | 2009 | 3 | 0.020 |
Why?
|
Waist Circumference | 1 | 2014 | 935 | 0.020 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2016 | 1149 | 0.020 |
Why?
|
Fibroblast Growth Factors | 1 | 2016 | 873 | 0.020 |
Why?
|
Quality of Life | 1 | 2011 | 13490 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2014 | 59629 | 0.020 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2010 | 619 | 0.020 |
Why?
|
Pyrroles | 1 | 2015 | 1124 | 0.020 |
Why?
|
Germany | 1 | 2010 | 883 | 0.020 |
Why?
|
Myocardial Infarction | 1 | 2009 | 11519 | 0.020 |
Why?
|
Adolescent | 3 | 2011 | 89169 | 0.020 |
Why?
|
Bone Marrow Examination | 1 | 2008 | 154 | 0.020 |
Why?
|
Retrospective Studies | 4 | 2018 | 81762 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2015 | 65371 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2013 | 2107 | 0.020 |
Why?
|
Indoles | 1 | 2015 | 1836 | 0.020 |
Why?
|
Cross-Sectional Studies | 3 | 2014 | 26379 | 0.020 |
Why?
|
Weight Gain | 1 | 2016 | 2359 | 0.020 |
Why?
|
Inflammation | 2 | 2016 | 10873 | 0.020 |
Why?
|
Prognosis | 2 | 2018 | 30010 | 0.020 |
Why?
|
Human Growth Hormone | 1 | 2010 | 651 | 0.020 |
Why?
|
Morbidity | 1 | 2010 | 1755 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2015 | 6847 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 6526 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2015 | 4912 | 0.010 |
Why?
|
Survival Rate | 1 | 2018 | 12840 | 0.010 |
Why?
|
Animals | 4 | 2016 | 169246 | 0.010 |
Why?
|
Thyroid Neoplasms | 1 | 2015 | 2360 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12543 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2014 | 39348 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2016 | 14488 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2013 | 4937 | 0.010 |
Why?
|
Sex Characteristics | 1 | 2010 | 2650 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2011 | 4528 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 8054 | 0.010 |
Why?
|
Mice | 2 | 2016 | 82029 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2015 | 22379 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2015 | 18349 | 0.010 |
Why?
|
Primary Health Care | 1 | 2010 | 4746 | 0.010 |
Why?
|
Prevalence | 1 | 2010 | 15869 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2009 | 7477 | 0.010 |
Why?
|
Infant | 1 | 2010 | 36535 | 0.000 |
Why?
|
Child, Preschool | 1 | 2010 | 42669 | 0.000 |
Why?
|
Child | 1 | 2010 | 80917 | 0.000 |
Why?
|